Navigation Links
Are your business and technology goals aligned?
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Are your business and technology goals aligned

(Date:7/28/2015)... 28, 2015  Kerastem Technologies announce that the Company ... FDA Center For Biologics Evaluation and Research (CBER) Office ... clinical trial investigating the safety and feasibility of the ... male pattern baldness (androgenic alopecia). The phase ... clinical work in Europe and ...
(Date:7/28/2015)... 2015 BioStructures, LLC, a privately held ... milestone of 4,000 implantations of Signafuse® Bioactive Bone ... early 2014 as a bone void filler indicated ... This is a distinguished status among recently cleared ... new synthetic products have received clearance with a ...
(Date:7/28/2015)... 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has granted to German life sciences entrepreneurs with ... commercialization of biotechnology (collectively, the "Optionee"), an option ... tumor vaccine technology (the "Technology"), including AEZS-120, the ... is ready to enter a Phase 1 clinical ...
(Date:7/28/2015)... NESS ZIONA, Israel ... CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company ... repair products, today announced that Shomrat Shurtz has ... September 20, 2015.      (Photo: ... brings over 25 years of experience in marketing, ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Revolutionary Bone Graft Exceeds Expectations 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2
... Systems and Tip Revenue Up Domestically and Internationally ... U.S. Sales Increase 8% Year-Over-Year ... HAYWARD, Calif., May 8 Thermage, Inc.,(Nasdaq: THRM ), ... its financial results for the first quarter ended,March 31, 2008., ...
... Company History; Full Year Revenue Up 13% Non-GAAP ... Year Company Provides FY09 Outlook for 13 ... May 8 Pharsight,Corporation (Nasdaq: PHST ), a ... clinical drug development, today announced,financial results for its fiscal ...
... 8 Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical company ... today reported its financial,results for the first quarter ... was $10.5 million, or $0.25 per share, compared ... same period in 2007., (Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO ...
Cached Biology Technology:Thermage Announces First Quarter 2008 Financial Results 2Thermage Announces First Quarter 2008 Financial Results 3Thermage Announces First Quarter 2008 Financial Results 4Thermage Announces First Quarter 2008 Financial Results 5Thermage Announces First Quarter 2008 Financial Results 6Thermage Announces First Quarter 2008 Financial Results 7Thermage Announces First Quarter 2008 Financial Results 8Thermage Announces First Quarter 2008 Financial Results 9Pharsight Achieves $7.6 Million In Quarterly Revenue 2Pharsight Achieves $7.6 Million In Quarterly Revenue 3Pharsight Achieves $7.6 Million In Quarterly Revenue 4Pharsight Achieves $7.6 Million In Quarterly Revenue 5Pharsight Achieves $7.6 Million In Quarterly Revenue 6Pharsight Achieves $7.6 Million In Quarterly Revenue 7Pharsight Achieves $7.6 Million In Quarterly Revenue 8Pharsight Achieves $7.6 Million In Quarterly Revenue 9Pharsight Achieves $7.6 Million In Quarterly Revenue 10Pharsight Achieves $7.6 Million In Quarterly Revenue 11Pharsight Achieves $7.6 Million In Quarterly Revenue 12Favrille Reports First Quarter 2008 Financial Results 2Favrille Reports First Quarter 2008 Financial Results 3Favrille Reports First Quarter 2008 Financial Results 4Favrille Reports First Quarter 2008 Financial Results 5Favrille Reports First Quarter 2008 Financial Results 6Favrille Reports First Quarter 2008 Financial Results 7Favrille Reports First Quarter 2008 Financial Results 8Favrille Reports First Quarter 2008 Financial Results 9
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... and unstable angina patients placed on beta-blocker therapy corresponds ... study by researchers at Washington University School of Medicine ... in Kansas City. The study appears in the September ... Medical Association. , "In our investigation of acute coronary ...
... understand extreme sea creaturesExtraordinary creatures who inhabit extreme underwater ... three-year project. These deep-sea communities could reveal an evolutionary ... give us clues to how life could exist onother ... - incredibly hot environments in the deep sea - ...
... developed virus that introduces a blood pressure-lowering gene into cells ... levels for four months promises to take gene therapy for ... Baylor College of Medicine in a report released online in ... blood pressure is one of the leading causes of death ...
Cached Biology News:Survival of heart patients on beta-blockers varies greatly with genetic variation 2Survival of heart patients on beta-blockers varies greatly with genetic variation 3Survival of heart patients on beta-blockers varies greatly with genetic variation 4Gene therapy to lower blood pressure just enough 2
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
... are neutral, porous styrene divinylbenzene ... of lipophilic polymers and other ... The beads are compatible with ... dimethylformamide, ketones, aromatics, methylene chloride, ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Simple operation and an easy-to-read LCD display characterize our Classic Light balances. * Taring range 0...1510 g...
Biology Products: